Experienced in Prostate Cancer

Jan P. De Boer

Antoni Van Leeuwenhoek
Amsterdam, NH, NL 
Experienced in Prostate Cancer
Antoni Van Leeuwenhoek
Amsterdam, NH, NL 
OverviewLocationsClinical Research

Overview

Jan De Boer practices in Amsterdam, Netherlands. De Boer is rated as an Experienced expert by MediFind in the treatment of Prostate Cancer. Their top areas of expertise are Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Gastrostomy, and Colonoscopy.

Their clinical research consists of co-authoring 74 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles in the study of Prostate Cancer.

Locations

Antoni van Leeuwenhoek
Amsterdam, NH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
Bioimmunoradiotherapy (BIR) With Concurrent Avelumab, Cetuximab and Radiotherapy as First Line Treatment in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Feasibility Study in Patients Unfit for Cisplatin
Bioimmunoradiotherapy (BIR) With Concurrent Avelumab, Cetuximab and Radiotherapy as First Line Treatment in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Feasibility Study in Patients Unfit for Cisplatin
Enrollment Status: Completed
Publish Date: December 11, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 1
View 2 Less Clinical Trials

74 Total Publications

Malignancy classification of thyroid incidentalomas using 18F-fluorodeoxy-d-glucose PET/computed tomography-derived radiomics.
Malignancy classification of thyroid incidentalomas using 18F-fluorodeoxy-d-glucose PET/computed tomography-derived radiomics.
Journal: Nuclear medicine communications
Published: July 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find De Boer's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile